Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon

This study has been completed.
Sponsor:
Information provided by:
Otsuka America Pharmaceutical
ClinicalTrials.gov Identifier:
NCT00048763
First received: November 7, 2002
Last updated: July 14, 2005
Last verified: July 2005
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: June 2003
  Estimated Primary Completion Date: No date given